Bank of Montreal’s Atara Biotherapeutics ATRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-6,152
Closed -$1.09K 4071
2022
Q2
$1.09K Buy
+6,152
New +$1M ﹤0.01% 2247
2021
Q3
Sell
-3,087
Closed -$1.28M 3804
2021
Q2
$1.28M Sell
3,087
-1,276
-29% -$455K ﹤0.01% 2332
2021
Q1
$1.55M Buy
4,363
+3,893
+828% +$1.72M ﹤0.01% 1909
2020
Q4
$234K Buy
470
+336
+251% +$155K ﹤0.01% 3143
2020
Q3
$47K Sell
134
-50
-27% -$17K ﹤0.01% 3457
2020
Q2
$70K Buy
+184
New +$46.5K ﹤0.01% 3255
2020
Q1
Sell
-444
Closed -$183K 4094
2019
Q4
$183K Buy
444
+80
+22% +$27.6K ﹤0.01% 3208
2019
Q3
$129K Buy
364
+31
+9% +$11.6K ﹤0.01% 3165
2019
Q2
$167K Buy
333
+149
+81% +$105K ﹤0.01% 3029
2019
Q1
$182K Sell
184
-23
-11% -$21.4K ﹤0.01% 2765
2018
Q4
$180K Buy
207
+12
+6% +$11.1K ﹤0.01% 2634
2018
Q3
$202K Hold
195
﹤0.01% 2736
2018
Q2
$180K Buy
195
+11
+6% +$11.8K ﹤0.01% 2818
2018
Q1
$179K Hold
184
﹤0.01% 2683
2017
Q4
$83K Hold
184
﹤0.01% 3072
2017
Q3
$76K Sell
184
-2,200
-92% -$829K ﹤0.01% 3082
2017
Q2
$834K Buy
+2,384
New +$919K ﹤0.01% 2063
2016
Q2
Sell
-32
Closed -$15K 4073
2016
Q1
$15K Buy
+32
New +$14.4K ﹤0.01% 3487

Other funds holding ATRA

Bank of Montreal's ATRA Position: Q3 2022 in Review

Bank of Montreal sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 6,152 shares — an estimated $1.09K sold.

Bank of Montreal first reported a position in ATRA in Q1 2016 and held it in 18 quarters. The position peaked at $1.55M in Q1 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Bank of Montreal reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Bank of Montreal sold 6,152 Atara Biotherapeutics shares in Q3 2022, an estimated $1.09K.
  • Bank of Montreal first reported a position in Atara Biotherapeutics in Q1 2016 and held it in 18 quarters.
  • Bank of Montreal's Atara Biotherapeutics position peaked at $1.55M in Q1 2021.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Bank of Montreal's 13F filing for Q3 2022, filed 10 Nov 2022.